Evaluation of Antibiotherapy Prescribed for Outpatients From Emergency Departments
NCT ID: NCT05350995
Last Updated: 2022-08-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
9600 participants
OBSERVATIONAL
2022-05-13
2023-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will be carried out in the form of a repeated survey on a given day (4 days, one across each season), carried out by the local mobile antibiotic therapy team, using a standardized grid. The survey will concern all the medical records of the patients visiting any emergency department on the days of the survey.
The evaluation of antibiotic therapies prescribed in discharge orders will be carried out in accordance with local management recommendations by the site investigator (infectious disease and/or emergency medicine specialist), who will assess whether the prescription is in accordance with the recommendations or not.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Does the National Health Insurance Card Allow us to Predict Antibiotic Resistance?
NCT02292160
Cost of Off-label Antibiotics in Osteoarticular Infections
NCT03335592
Antibiotic Resistance in Danish EDs.
NCT03352167
: Bacterial Infections in Injecting Drug Users
NCT04550767
Exposure to Antibiotics and Incidence of Bacteraemia Caused by Resistant Bacteria
NCT04065750
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
No intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥18
Exclusion Criteria
* Patient under guardianship or curatorship
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Henri Mondor University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Clement OURGHANLIAN
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clément Ourghanlian, PharmD
Role: PRINCIPAL_INVESTIGATOR
Henri Mondor University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Henri Mondor
Créteil, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Clément Ourghanlian, PharmD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U2TI-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.